# US 8,278,305 B2 · Myosin light chain kinase inhibitor compounds, compositions and related methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,305 B2
- Document ID: US8278305B2
- Status: Granted
- Kind: B2
- Application number: 12/786,676
- Filed: 2010-05-25
- Published: 2010-09-23
- Granted: 2012-10-02
- Earliest claimed: 2006-07-21
- Assignees: Northwestern University
- Inventors: Daniel Martin Watterson; Linda J. Van Eldik; Heather Behanna; Hantamalala Ralay Ranaivo
- Web page: https://patentgrep.com/patent/US8278305B2

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 237/20: Nitrogen atoms (nitro radicals C07D237/12)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pyridazinyl compounds, compositions and related methods of use.

## Claims

### Claim 1

A method of inhibiting myosin light chain kinase activity, said method comprising:
providing a medium comprising a myosin light chain kinase; and
contacting said medium with a compound of a formula
wherein R3 is selected from H and alkyl moieties; R6 is selected from H, halo, alkyl, aryl and heterocyclic moieties; n is an integer from 8 to 14; and X is (CH2)2Y, where Y is selected from substituted and unsubstituted pyrrolidinyl, substituted and unsubstituted pyrrolyl, substituted and unsubstituted pyrazolyl, substituted and unsubstituted imidazolyl and substituted and unsubstituted cyclopentyl moieties; and salts thereof, said compound in an amount sufficient to at least partially inhibit said kinase activity.

### Claim 2 (depends on 1)

The method of claim 1 wherein said contact is in vivo.

### Claim 3 (depends on 2)

The method of claim 2 contacting at least one of epithelial and endothelial tissue exhibiting barrier dysfunction.

### Claim 4 (depends on 3)

The method of claim 3 wherein the at least one of epithelial and endothelial tissue exhibiting barrier dysfunction that is contacted is injured pulmonary tissue.

### Claim 5 (depends on 3)

The method of claim 3 wherein said compound is in a pharmaceutical composition.

### Claim 6 (depends on 1)

The method of claim 1 wherein R3 is hydrogen, R6 is halo or phenyl, n is 10, and X is selected from 6-phenylpyridazin-3-yl, 1H-imidazol-2-yl methyl, 1-methylpyrrolidin-2-yl methyl, pyrrolidin-2-yl methyl and cyclopentyl methyl.

### Claim 7 (depends on 6)

The method of claim 6 wherein the compound is selected from:
11-(6-imino-3-phenylpyridazin-1(6H)-yl)-N-(6-phenylpyridazin-3-yl)undecanamide;
11-(3-chloro-6-iminopyridazin-1(6H)-yl)-N-(6-phenylpyridazin-3-yl)undecanamide;
N-((1H-imidazol-2-yl)methyl)-11-(6-imino-3-phenylpyridazin-1(6H)-yl)undecanamide;
11-(6-imino-3-phenylpyridazin-1(6H)-yl)-N-((1-methylpyrrolidin-2-yl)methyl)undecanamide;
11-(6-imino-3-phenylpyridazin-1(6H)-yl)-N-(pyrrolidin-2-ylmethyl)undecanamide; and
N-(cyclopentylmethyl)-11-(6-imino-3-phenylpyridazin-1(6H)-yl)undecanamide.

### Claim 8

A method of treating progression of acute tissue injury, said method comprising:
providing at least one of epithelial and endothelial tissue with barrier dysfunction, and
contacting said tissue with a compound of a formula
wherein R3 is selected from H and alkyl moieties; R6 is selected from H, halo, alkyl, aryl and heterocyclic moieties; n is an integer from 8 to 14; and X is (CH2)2Y, where Y is selected from substituted and unsubstituted pyrrolidinyl, substituted and unsubstituted pyrrolyl, substituted and unsubstituted pyrazolyl, substituted and unsubstituted imidazolyl and substituted and unsubstituted cyclopentyl moieties; and salts thereof, said compound in a therapeutically sufficient amount.

### Claim 9 (depends on 8)

The method of claim 8 wherein said contact is in vivo.

### Claim 10 (depends on 9)

The method of claim 9 wherein the at least one of epithelial and endothelial tissue exhibiting barrier dysfunction that is contacted is injured pulmonary tissue.

### Claim 11 (depends on 9)

The method of claim 9 wherein said therapeutic amount is selective for MLCK inhibition over inhibition of at least one of DAPK, PKC and PKA.

### Claim 12 (depends on 11)

The method of claim 11 wherein said MLCK inhibition is confirmed against MLCK210 (KO) mice.

### Claim 13 (depends on 8)

The method of claim 8 wherein R3 is hydrogen, R6 is halo or phenyl, n is 10, and X is selected from 6-phenylpyridazin-3-yl, 1H-imidazol-2-yl methyl, 1-methylpyrrolidin-2-yl methyl, pyrrolidin-2-yl methyl and cyclopentyl methyl.

### Claim 14 (depends on 13)

The method of claim 13 wherein the compound is selected from:
11-(6-imino-3-phenylpyridazin-1(6H)-yl)-N-(6-phenylpyridazin-3-yl)undecanamide;
11-(3-chloro-6-iminopyridazin-1(6H)-yl)-N-(6-phenylpyridazin-3-yl)undecanamide;
N-((1H-imidazol-2-yl)methyl)-11-(6-imino-3-phenylpyridazin-1(6H)-yl)undecanamide;
11-(6-imino-3-phenylpyridazin-1(6H)-yl)-N-((1-methylpyrrolidin-2-yl)methyl)undecanamide;
11-(6-imino-3-phenylpyridazin-1(6H)-yl)-N-(pyrrolidin-2-ylmethyl)undecanamide; and
N-(cyclopentylmethyl)-11-(6-imino-3-phenylpyridazin-1(6H)-yl)undecanamide.

### Claim 15

A method for selective kinase inhibition, said method comprising:
providing a pyridazinylalkaneamide compound of a formula
wherein R3 is selected from H and alkyl moieties; R6 is selected from H, halo, alkyl, aryl and heterocyclic moieties; n is an integer from 8 to 14; and X is (CH2)2Y, where Y is selected from substituted and unsubstituted pyrrolidinyl, substituted and unsubstituted pyrrolyl, substituted and unsubstituted pyrazolyl, substituted and unsubstituted imidazolyl and substituted and unsubstituted cyclopentyl moieties; and
contacting said compound with a medium comprising a myosin light chain kinase, said compound in an amount sufficient to at least partially inhibit said kinase activity, said X moiety providing said compound inhibition activity selective over at least one of death-associated protein kinase, protein kinase A and protein kinase C.

### Claim 16 (depends on 15)

The method of claim 15 wherein said X moiety provides said compound an aqueous solubility of log S about ≦−3.
